<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="research-article" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">cells</journal-id>
      <journal-title>Cells</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Cells</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Cells</abbrev-journal-title>
      <issn pub-type="epub">2073-4409</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/cells5020019</article-id>
      <article-id pub-id-type="publisher-id">cells-05-00019</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Generation and Characterization of Vascular Smooth Muscle Cell Lines Derived from a Patient with a Bicuspid Aortic Valve</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lazar-Karsten</surname>
            <given-names>Pamela</given-names>
          </name>
          <xref rid="af1-cells-05-00019" ref-type="aff">1</xref>
          <xref rid="fn1-cells-05-00019" ref-type="fn">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Belge</surname>
            <given-names>Gazanfer</given-names>
          </name>
          <xref rid="af2-cells-05-00019" ref-type="aff">2</xref>
          <xref rid="fn1-cells-05-00019" ref-type="fn">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schult-Badusche</surname>
            <given-names>Detlev</given-names>
          </name>
          <xref rid="af1-cells-05-00019" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Focken</surname>
            <given-names>Tim</given-names>
          </name>
          <xref rid="af2-cells-05-00019" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radtke</surname>
            <given-names>Arlo</given-names>
          </name>
          <xref rid="af2-cells-05-00019" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>Junfeng</given-names>
          </name>
          <xref rid="af1-cells-05-00019" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ranabhat</surname>
            <given-names>Pramod</given-names>
          </name>
          <xref rid="af1-cells-05-00019" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mohamed</surname>
            <given-names>Salah A.</given-names>
          </name>
          <xref rid="af1-cells-05-00019" ref-type="aff">1</xref>
          <xref rid="c1-cells-05-00019" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Kalyuzhny</surname>
            <given-names>Alexander E.</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-cells-05-00019"><label>1</label>Department of Cardiac and Thoracic Vascular Surgery, University of Luebeck, D-23538 Luebeck, Germany; <email>pamela.lazar-karsten@uksh.de</email> (P.L.-K.); <email>detlev.schult-badusche@uksh.de</email> (D.S.-B.); <email>junfeng.yan@uksh.de</email> (J.Y.); <email>pramod.ranabhat@student.uni-luebeck.de</email> (P.R.)</aff>
      <aff id="af2-cells-05-00019"><label>2</label>Center of Human Genetics and Genetic Counselling, University of Bremen, D-28359 Bremen, Germany; <email>belge@uni-bremen.de</email> (G.B.); <email>focken@uni-bremen.de</email> (T.F.); <email>arlo.radtke@gmx.de</email> (A.R.)</aff>
      <author-notes>
        <corresp id="c1-cells-05-00019"><label>*</label>Correspondence: <email>salah.mohamed@uksh.de</email>; Tel.: +49-451-500-6425; Fax: +49-451-500-2051</corresp>
		<fn id="fn1-cells-05-00019">
          <label>&#x2020;</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>04</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">        <month>06</month>
        <year>2016</year>
      </pub-date>
      <volume>5</volume>
      <issue>2</issue>
      <elocation-id>19</elocation-id>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>09</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>04</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by the authors.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access">
          <p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</p>
        </license>
      </permissions>
      <abstract>
        <p>Thoracic aortic dilation is the most common malformation of the proximal aorta and is responsible for 1%&#x2013;2% of all deaths in industrialized countries. In approximately 50% of patients with a bicuspid aortic valve (BAV), dilation of any or all segments of the aorta occurs. BAV patients with aortic dilation show an increased incidence of cultured vascular smooth muscle cell (VSMC) loss. In this study, VSMC, isolated from the ascending aorta of BAV, was treated with Simian virus 40 to generate a BAV-originated VSMC cell line. To exclude any genomic DNA or cross-contamination, highly polymorphic short tandem repeats of the cells were profiled. The cells were then characterized using flow cytometry and karyotyping. The WG-59 cell line created is the first reported VSMC cell line isolated from a BAV patient. Using an RT<sup>2</sup> Profiler PCR Array, genes within the TGF&#x3B2;/BMP family that are dependent on losartan treatment were identified. Endoglin was found to be among the regulated genes and was downregulated in WG-59 cells following treatment with different losartan concentrations, when compared to untreated WG-59 cells.</p>
      </abstract>
      <kwd-group>
        <kwd>bicuspid aortic valve</kwd>
        <kwd>vascular smooth muscle cell</kwd>
        <kwd>WG-59 cell line</kwd>
        <kwd>losartan</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-cells-05-00019" sec-type="intro">
      <title>1. Introduction</title>
      <p>Vascular smooth muscle cells (VSMCs) are of mesodermal origin and are present in various organs (essential parts of the cardiovascular system, the respiratory system, the gastrointestinal tract and the urinary tract). The VSMC phenotype is diverse [<xref ref-type="bibr" rid="B1-cells-05-00019">1</xref>]. In normal mature blood vessels, the predominant phenotype is the quiescent or differentiated (contractile) phenotype, which regulates blood vessel diameter and blood flow [<xref ref-type="bibr" rid="B2-cells-05-00019">2</xref>]. This phenotype can switch into the proliferative, migratory and synthetic type, which is crucial for repair in response to injury and the synthesis of extracellular matrix proteins, such as fibroblast growth factor, epidermal growth factor, platelet-derived growth factor, transforming growth factor beta (TGF&#x3B2;), vascular endothelial growth factor and angiotensin II (AngII) [<xref ref-type="bibr" rid="B3-cells-05-00019">3</xref>]. VSMCs are the main component of the aortic media, and their dysfunction plays an important role in many different arterial diseases [<xref ref-type="bibr" rid="B4-cells-05-00019">4</xref>].</p>
      <p>The loss of VSMCs is a characteristic of degenerative remodeling within the medial layer of thoracic aortic aneurysms and dissection (TAAD) tissue. Moreover, patients with bicuspid aortic valve (BAV) and aortic aneurysms exhibit VSMC alpha actin gene mutations (<italic>ACTA2</italic>, mapped to chromosome 10q) [<xref ref-type="bibr" rid="B5-cells-05-00019">5</xref>,<xref ref-type="bibr" rid="B6-cells-05-00019">6</xref>]. In addition, a failure in switching from a synthetic to contractile VSMC phenotype generates intimal vascular lesions. VSMCs of patients with BAV are less mature than those of tricuspid aortic valve (TAV) patients [<xref ref-type="bibr" rid="B7-cells-05-00019">7</xref>]. There is a significant difference between the aortic wall structure in BAV patients compared to that in TAV patients, who present a thinner wall, lower expression of typical maturation markers, such as SM22 &#x3B1;, calponin, &#x3B1; smooth muscle actin and nearly no expression of smoothelin. BAV represents a high risk factor of TAAD. Patients with BAV are more frequently affected by TAAD and at a younger age [<xref ref-type="bibr" rid="B8-cells-05-00019">8</xref>,<xref ref-type="bibr" rid="B9-cells-05-00019">9</xref>].</p>
      <p>VSMCs of the aortic valve and ascending aorta share a common embryonic origin, the cardiac neural crest [<xref ref-type="bibr" rid="B10-cells-05-00019">10</xref>,<xref ref-type="bibr" rid="B11-cells-05-00019">11</xref>]. Thus, analyzing the diseased ascending aorta can provide useful information about malformations of the aortic valve. The dilation of the ascending aorta represents 43% of arterial diseases with an upward trend. Due to the high mortality and lack of symptoms, it is a special challenge to physicians, internists and cardiac surgeons. Since patients with BAV show increased susceptibility to the development of ascending aortic dilation, studying the aortic wall structure may render interesting insights. VSMC culture may provide useful help for this matter.</p>
      <p>We used VSMCs isolated from a patient with BAV/TAAD and performed a Simian virus 40 (SV-40) transfection to generate an immortalized VSMC cell line. We then characterized these cells and performed spectral karyotyping (SKY) to eliminate potential contamination by foreign DNA.</p>
      <p>Since the TGF&#x3B2; pathway plays an important role in the pathogenesis of TAAD, we analyzed the effect of losartan on the expression of 84 genes related to the TGF&#x3B2; pathway in VSMCs. The disease Marfan syndrome (MFS), a connective tissue disorder, is caused by a mutation in the <italic>Fibrillin-1</italic> gene. This mutation leads to overexpression of TGF&#x3B2; signaling in MFS. Loeys&#x2013;Dietz syndrome (LDS), another disease with particularly strong predisposition for arterial aneurysm, shows decreased TGF&#x3B2; signaling. This leads to the assumption that TGF&#x3B2; dysregulation may promote the aneurysmal process in the aorta, thus arousing interest in further investigations of TGF&#x3B2;. In the present study, the AngII type 1 receptor (AT<sub>1</sub>R) blocker losartan was used as a potential TGF&#x3B2; signaling inhibitor. Losartan reduces aortic growth and blunts TGF&#x3B2; signaling in the aortic media of fibrillin-1-deficient mice, thereby indicating an impact of the renin-angiotensin system in thoracic aortic aneurysm [<xref ref-type="bibr" rid="B12-cells-05-00019">12</xref>].</p>
    </sec>
    <sec id="sec2-cells-05-00019">
      <title>2. Material and Methods</title>
      <sec id="sec2dot1-cells-05-00019">
        <title>2.1. Cell Culture of Primary VSMCs</title>
        <p>A 46-year-old male patient was diagnosed with BAV and fusion of the right and non-coronary cusps. He was admitted to the hospital to undergo aortic valve replacement due to Grade 3 pre-valve stenosis. Ascending aorta tissue was removed during surgery; VSMCs were isolated out of the tunica media for cell culture. The vascular smooth muscle sample was minced and treated with 0.26% collagenase (250 U/mL, Serva; Heidelberg, Germany) at 37 &#xB0;C for 3&#x2013;4 h. Following centrifugation, the pellet was resuspended in culture medium (TC199 supplemented with Earle's balanced salt solution, 20% fetal bovine serum (FBS), 200 IU/mL penicillin and 200 &#xB5;g/mL streptomycin and incubated at 37 &#xB0;C, 5% CO<sub>2</sub>). The monolayer culture was passaged by standard trypsin dispersion and resuspended in culture medium.</p>
      </sec>
      <sec id="sec2dot2-cells-05-00019">
        <title>2.2. Generating the WG-59 Cell Line from Primary VSMC Culture</title>
        <p>To generate a human ascending aorta vascular smooth muscle cell line with an extended life span, primary smooth muscle cells isolated from the biopsy material were transfected with a mammalian expression vector containing genes encoding the SV-40 early region, according to Kazmierczak <italic>et al.</italic> [<xref ref-type="bibr" rid="B13-cells-05-00019">13</xref>]. Initial foci of transformed cells appeared 26 days post-transfection.</p>
      </sec>
      <sec id="sec2dot3-cells-05-00019">
        <title>2.3. Fluorescence in Situ Hybridization Mapping of the SV-40 Early Region in VSMCs after Transfection</title>
        <p>FISH studies were performed on pre-banded metaphase chromosomes from transformed muscle cells. For hybridization, SV-40 plasmid DNA was used with DNA probes approximately 7.5 kb in length, as described previously [<xref ref-type="bibr" rid="B13-cells-05-00019">13</xref>]. The hybridization procedure was performed according to the manufacturer&#x2019;s instructions (Roche Diagnostics; Mannheim, Germany). The DNA probes were treated with digoxigenin (DIG, Roche Diagnostics; Mannheim, Germany) and dissolved in hybridization media followed by overnight incubation in a moist chamber at 37 &#xB0;C. Labeled probes were detected using anti-digoxigenin&#x2013;fluorescein isothiocyanate conjugates (FITC, Roche Diagnostics; Mannheim, Germany). Chromosomes were counterstained with propidium iodide. In total, 20 metaphase events were scored for analysis.</p>
      </sec>
      <sec id="sec2dot4-cells-05-00019">
        <title>2.4. Immunofluorescence for Large T-Antigen in the WG-59 Cell Line </title>
        <p>Large SV-40 T-antigen expression was analyzed according to Kazmierczak <italic>et al.</italic> [<xref ref-type="bibr" rid="B13-cells-05-00019">13</xref>]. Approximately 5 &#xD7; 10<sup>4</sup> VSMCs were plated onto cover slips and incubated in TC199 culture medium supplemented with 20% (v/v) FBS for 48 h. Cells were washed with phosphate-buffered saline (PBS) and fixed with methanol and acetone (10 min each at &#x2212;20 &#xB0;C). Cells were incubated for 30 min with mouse anti-SV40 large T-antigen, washed in PBS and incubated with FITC-labeled goat anti-mouse IgG (Merck Biosciences; Schwalbach, Germany) for another 30 min.</p>
      </sec>
      <sec id="sec2dot5-cells-05-00019">
        <title>2.5. Chromosome Analysis with Spectral Karyotyping of the WG-59 Cell Line</title>
        <p>For chromosome analysis, we used exponentially-growing cultures of transformed VSMCs. After a 24-h growth period, metaphase chromosome spreads were prepared using colcemid (0.06 &#xB5;g/mL for 40 min) in order to arrest the cultured cells during mitosis. A hypotonic solution (1:6 ratio of culture medium in aqua bidestllata. and a fixative (3:1 ratio of methanol and acetic acid) were sequentially applied. Finally, the chromosome suspension was dropped onto glass slides. The chromosomes were GTG-banded according to routine techniques. The karyotype description followed the International System for Human Cytogenetic Nomenclature 2013 (ISCN). SKY was performed according to the manufacturer&#x2019;s protocol (Applied Spectral Imaging (ASI), Migdal Ha&#x2019;Emek, Israel). To describe the karyotype, 12 metaphase spreads were acquired with an Axioskop 2 plus microscope (Carl Zeiss, G&#xF6;ttingen, Germany) and analyzed using the SkyView Software. A composite karyotyping was done according to ISCN 2013.</p>
      </sec>
      <sec id="sec2dot6-cells-05-00019">
        <title>2.6. Highly Polymorphic Short Tandem Repeat Profiling</title>
        <p>DNA was isolated from patient tissue and WG-59 using the QIAamp DNA mini kit (Hilden, Germany) according to the manufacturer&#x2019;s protocol. DNA concentration was measured using the NanoDrop instrument (Wilmington, NC, USA). To screen the cells against cross-contamination and in order to authenticate them as a human cell line originating from the donor&#x2019;s material as the donor tissue, short tandem repeat (STR) typing was performed. DNA profiling was carried out using 8 different and highly polymorphic STR loci. Furthermore, we tested the samples for the presence of mitochondrial DNA sequences from rodent cells, such as mouse, rat, Chinese and Syrian hamster, according to the manufacturer&#x2019;s protocol (DSMZ, Braunschweig, Germany).</p>
      </sec>
      <sec id="sec2dot7-cells-05-00019">
        <title>2.7. Characterization of the WG-59 Cell Line</title>
        <p>The WG-59 cell characterization was performed by flow cytometry at the 20th passage. In brief, 100 &#xB5;L of 1 &#xD7; 10<sup>6</sup> cells were incubated for 20 min at 4 &#xB0;C in BD Cytofix/Cytoperm (BD Bioscience, Heidelberg, Germany) in order to fix and the cells and permeabilize the cell membrane. Cells were then washed with 10% BD Wash/Perm Solution (BD Bioscience) and incubated with antibodies against &#x3B1;-actin (R&amp;D Systems, Minneapolis, MN, USA), myosin heavy chain (R&amp;D Systems, Minneapolis, MN, USA), calponin (Acris, San Diego, CA, USA) and smoothelin (Acris, San Diego, CA, USA) in a total volume of 50 &#xB5;L for 30 min. Cells were washed again in 10% BD Wash/Perm Solution and were resuspended in 300&#x2013;400 &#xB5;L BD Staining Buffer (BD Bioscience). The measurement was performed on a benchtop analyzer LSR II (Becton Dickenson, Heidelberg, Germany). FlowJo software (Tree Star, Inc., Ashland, OR, USA) was used for data analysis. To exclude non-specific binding, mouse IgG1 and IgG2a isotype controls (BioLegend, London, UK) were used.</p>
      </sec>
      <sec id="sec2dot8-cells-05-00019">
        <title>2.8. Collagen-Based Cell Contraction Assay</title>
        <p>The contractility of the WG-59 cells at a passage of 50 was tested by subjecting the cells to a collagen-based contraction analysis, using the cell contraction assay (Cell Biolabs Inc. San Diego, CA, USA) according to the manufacturer&#x2019;s protocol. Here, the cells were suspended in the DMEM media provided, with a density of 5 &#xD7; 10<sup>6</sup> cells per mL. The collagen lattice was prepared by mixing 1 part of the cell suspension with 4 parts of cold collagen gel solution (prepared with the supplied kit solutions). To polymerize the collagen matrix, 0.5 mL of the cell-collagen mixture were then added to each well in a 24-well plate and incubated for 1 h at 37 &#xB0;C. After polymerization, 1 mL of the culture medium was added to each collagen gel lattice. The cell culture was incubated for 2 days. To initiate contraction, the collagen gel was gently released from the side of the culture dishes with a sterile spatula. The size of the matrix was measured at the beginning and end of the assay.</p>
      </sec>
      <sec id="sec2dot9-cells-05-00019">
        <title>2.9. TGF&#x3B2; Pathway and Data Analysis</title>
        <p>The WG-59 cell line was grown to 80% confluency and incubated in serum-free media for 24 h. Losartan (1 &#xB5;M) was added to the cells for 24 h. Cellular RNA was extracted with TRIzol (Life Technologies, Darmstadt, Germany). RNA was reverse transcribed into cDNA using theSuperScript II-Kit (Life Technologies, Darmstadt; Germany), and expression of 84 genes related to the TGF&#x3B2; pathway was quantified using the RT<sup>2</sup> Profiler PCR Array according to the manufacturer&#x2019;s protocol (Qiagen, Hilden, Germany). Three independently-treated samples and three controls were measured using the RT<sup>2</sup> Profiler PCR Array.</p>
        <p>Data analysis was performed with RT<sup>2</sup> Profiler PCR Array Data Analysis Version 3.5. The sample results were normalized to GAPDH and &#x3B1;-actin. Samples treated with losartan were compared to cells without treatment (control group). Genes with at least a two-fold change in expression and a <italic>p</italic>-value &lt; 0.05 were considered significantly regulated.</p>
      </sec>
      <sec id="sec2dot10-cells-05-00019">
        <title>2.10. Single Gene Expression Analysis</title>
        <p>To confirm the TGF&#x3B2; pathway analysis results and to further investigate the effect of losartan in various concentrations, the expression of <italic>endoglin</italic> and <italic>CDC25A</italic> was measured by single real-time RT-PCR. SYBR Green was used to detect expression changes dependent on different losartan concentrations (1, 10 and 100 &#xB5;M) and compared to a non-treated control cell culture. As an internal control for normalization, 18S RNA was used. Gene expression analysis was performed using the Applied Biosystems 7000 Real-Time PCR System (Applied Biosystems by Life Technologies, Darmstadt, Germany).</p>
      </sec>
    </sec>
    <sec id="sec3-cells-05-00019" sec-type="results">
      <title>3. Results</title>
      <sec id="sec3dot1-cells-05-00019">
        <title>3.1. Generating and Characterizing the WG-59 Cell Line</title>
        <p>The WG-59 cell line was generated from VSMCs of the tunica media of an ascending aorta. Immortalization was performed after SV-40 transfection. Initial foci of transformed cells appeared 26 days post-transfection (<xref ref-type="fig" rid="cells-05-00019-f001">Figure 1</xref>A). Cells showed altered morphology, smaller cell size, loss of contact inhibition, foci formation and T-antigen expression (<xref ref-type="fig" rid="cells-05-00019-f001">Figure 1</xref>B). Transformed cells showed higher proliferation capacity when compared to non-transformed cells. While non-transformed cells had a maximum lifetime of 15 passages, we were able to cultivate the transformed cells up to the 70th passage. Changes of the morphology and proliferation were monitored daily under the microscope (<xref ref-type="fig" rid="cells-05-00019-f001">Figure 1</xref>C).</p>
      </sec>
      <sec id="sec3dot2-cells-05-00019">
        <title>3.2. Cytogenic Characteristics and DNA Profile of the WG-59 Cell Line</title>
        <p>To cytogenetically characterize the cell line, we investigated 60 metaphases (55th passage) where we found the largest (92) and the least (70) number of chromosomes (<xref ref-type="table" rid="cells-05-00019-t001">Table 1</xref>). The average number of chromosomes per metaphase is 76.6, so each chromosome should be present in three to four copies. We karyotyped 17 of the 60 metaphases and found the loss of both Y-chromosomes in ten metaphases. In the other five karyotyped metaphases, only one Y-chromosome was present. In addition to different translocations and deletions of several chromosomes, the loss of autosomal chromosomes 2, 3, 4, 8, 9, 10, 13, 15, 17, 18, 19, 20 was observed in most metaphases. The spectral karyotyping revealed a pseudotriploid karyotype with a chromosome count of 70&#x2013;91. Several aberrations were present in duplicates and clonal numbers. Single cell aberrations could be detected in nearly every metaphase (<xref ref-type="fig" rid="cells-05-00019-f002">Figure 2</xref>).</p>
        <p>The sample WG-59 cell line was derived from WG-59 donor tissue, with full authentication stated (<xref ref-type="table" rid="cells-05-00019-t002">Table 2</xref>). Furthermore, using a detection limit of 1:10<sup>5</sup>, no mitochondrial sequences from mouse, rat or Chinese and Syrian hamster cells could be detected in WG-59 samples. The samples were derived from pure human cell cultures. Generated STR profiles of the WG-59 cell line showed no match with any reference cell line (<xref ref-type="fig" rid="cells-05-00019-f003">Figure 3</xref>), as indicated by the search of the databases of cell banks ATCC (USA), Japanese Collection of Research Bioresources Cell Bank (Japan), RIKEN (Japan), Korean Cell Line Bank (Korea), Wistar Institute (USA), European Collection of Authenticated Cell Cultures (UK) and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Germany). The WG-59 cell line shows a missing Y-chromosome in the STR analysis (<xref ref-type="table" rid="cells-05-00019-t002">Table 2</xref>).</p>
      </sec>
      <sec id="sec3dot3-cells-05-00019">
        <title>3.3. Flow Cytometry Analysis of the WG-59 Cell Line</title>
        <p>The purity of isolated cells was analyzed by flow cytometry. The cells expressed the typical VSMC proteins, e.g., &#x3B1; smooth muscle actin and myosin heavy chain. As shown in <xref ref-type="fig" rid="cells-05-00019-f004">Figure 4</xref>A&#x2013;C, 84.4% of SMCs were double positive for &#x3B1; smooth muscle actin and myosin heavy chain; 86.5% were positive for &#x3B1; smooth muscle actin and calponin; and 83.9% for myosin heavy chain (SM22) and calponin; whereas negative cells accounted for 2.98%, 2.07% and 5.66%, respectively. WG-59 cells showed an almost lack of smoothelin expression, as already observed by Grewal <italic>et al.</italic> [<xref ref-type="bibr" rid="B7-cells-05-00019">7</xref>] and declared typical for VSMC isolated from BAV patients (<xref ref-type="fig" rid="cells-05-00019-f004">Figure 4</xref>G,H).</p>
      </sec>
      <sec id="sec3dot4-cells-05-00019">
        <title>3.4. Cell Contraction Assay</title>
        <p>Using the cell contraction assay, we aimed to visualize the contraction ability of WG-59 cells. The size of the collagen gel matrix was measured at the beginning and end of the assay. However, no size change could be detected at any time during the assay incubation period of seven days after stress release.</p>
      </sec>
      <sec id="sec3dot5-cells-05-00019">
        <title>3.5. Gene Expression Analysis of the TGF&#x3B2; Pathway</title>
        <p>Various gene expressions of the TGF&#x3B2; pathway were significantly different in losartan-treated VSMCs compared to untreated cells. However, the expression differences were low; none of the significant changes were over two-fold (<xref ref-type="fig" rid="cells-05-00019-f005">Figure 5</xref>). The scatter plot showed a positive and strong correlation between losartan-treated cells and non-treated culture. Among the genes showing the most significant expression changes were <italic>endoglin</italic> (1.14-fold downregulation after losartan treatment; <italic>p</italic> = 0.0052) and <italic>CDC25A</italic> (1.24-fold downregulation after losartan treatment; <italic>p</italic> = 0.0008, <xref ref-type="table" rid="cells-05-00019-t003">Table 3</xref>).</p>
        <p><italic>Endoglin</italic> and <italic>CDC25A</italic> expressions were measured after treating cells with three different concentrations of losartan (<xref ref-type="fig" rid="cells-05-00019-f006">Figure 6</xref>). Single real-time RT-PCR analysis confirmed gene expression array results. Endoglin was downregulated in both measurements. Increasing the losartan concentration caused downregulation of <italic>endoglin</italic> expression, but not significantly.</p>
      </sec>
    </sec>
    <sec id="sec4-cells-05-00019" sec-type="discussion">
      <title>4. Discussion</title>
      <p>TAAD is estimated to occur in three cases per 100,000 individuals per year and is a major cause of death [<xref ref-type="bibr" rid="B14-cells-05-00019">14</xref>]. Some publications define TAAD by medial degeneration characterized by VSMC loss, fragmentation and depletion of elastic fibers, as well as accumulation of proteoglycans and glycosaminoglycans within cell-depleted aorta tunica media areas [<xref ref-type="bibr" rid="B15-cells-05-00019">15</xref>]. Due to the role of VSMCs in TAAD, it is crucial to investigate the potential contribution of VSMC to TAAD development. An immortalized VSMC cell line could be an essential and powerful tool for this investigation.</p>
      <p>In this study, we generated an immortalized VSMC cell line, WG-59, isolated from the aorta of a BAV patient. The WG-59 cell line showed a missing Y-chromosome in STR analysis. The phenomenon of uniparental disomy is sometimes observed during cell line establishments and is most probably due to loss of function mutations within DNA repair genes. Connected to bottlenecking outgrowths of sub-lines, these modifications can become visible.</p>
      <p>Infection of human cells by SV-40 alters the cells and leads to characteristic changes. Transformation can be defined by expression of SV-40 large T-antigen, loss of contact inhibition, enhanced growth potential and growth in low-serum media [<xref ref-type="bibr" rid="B16-cells-05-00019">16</xref>]. Immortalized cell cultures usually enter a &#x201C;crisis&#x201D; characterized by reduced proliferation, loss of attachment to the flask and the development of multinucleated or giant cells [<xref ref-type="bibr" rid="B17-cells-05-00019">17</xref>]. Cultures surviving this crisis show very high growth capacity and provide an excellent working base for long-term experiments. To confirm our immortalized WG-59 cell culture containing VSMC, cell shape was observed daily by microscopy, and flow cytometric measurements were performed.</p>
      <p>Cytogenetic studies of WG-59 cells showed polyploid karyotypes with complex rearrangements, loss of different autosomal chromosomes and both Y-chromosomes. The karyotype instability of the Y-chromosomes in cells is typical for the loss of the small chromosomes in rapidly-proliferating cells similar to immortalized SV-40 cell lines [<xref ref-type="bibr" rid="B13-cells-05-00019">13</xref>]. This might be the reason for the alteration in the cytogenic profile of the cell culture, e.g., loss of the amelogenin marker in STR analysis. The telomeric associations of the acrocentric chromosomes characteristic for SV-40 transformed cells were also found [<xref ref-type="bibr" rid="B18-cells-05-00019">18</xref>].</p>
      <p>The expression of typical VSMC &#x3B1; smooth muscle cell actin, myosin heavy chain and calponin was detected in more than 95% of the cells (single- and double-positive cells), indicating that the culture consisted mainly of VSMCs. Other than VSMCs of TAV patients, VSMCs isolated from BAV patient tissue lack smoothelin expression, as shown by Grewal <italic>et al.</italic> [<xref ref-type="bibr" rid="B7-cells-05-00019">7</xref>] and confirmed in the present study.</p>
      <p>The VSMCs phenotype varies from quiescent and contractile to proliferative and synthetic to execute a diversity of functions. Unlike the contractile phenotype, the synthetic phenotype possesses a high proliferative index and a low expression of contractile apparatus proteins [<xref ref-type="bibr" rid="B19-cells-05-00019">19</xref>]. <italic>In vitro</italic>, the synthetic VSMC phenotype tends to grow in a hill and valley morphology, which has been observed in previous studies of WG-59 VSMC cultures conducted by this group [<xref ref-type="bibr" rid="B20-cells-05-00019">20</xref>]. Thus, the hill and valley morphology observed in these cultured cells may be due to the fact that WG-59 cells are of a synthetic and proliferative phenotype and therefore express only a low amount of contractile proteins. This would explain the fact that no observable change in the collagen matrix size or in the contractility of the WG-59 cell culture in the cell contraction assay was detected. This would explain the fact that we were not able to observe any collagen size change and therefore contractility of WG-59 in the cell contraction assay.</p>
      <p>The exact mechanisms leading to aortic aneurysms in the ascending aorta of bicuspid aortic valve (BAV) are poorly understood. It is unclear whether aortic changes in patients with BAV (large aortic diameter, reduced arterial elasticity and increased degeneration of the aortic media layer) relate to hemodynamic forces due to aortic valve dysfunction or whether these abnormalities result from an aortic wall weakness caused by genetic defects [<xref ref-type="bibr" rid="B21-cells-05-00019">21</xref>]. Several BAV studies have revealed high rates of VSMC apoptosis [<xref ref-type="bibr" rid="B22-cells-05-00019">22</xref>,<xref ref-type="bibr" rid="B23-cells-05-00019">23</xref>], similar to those observed in MFS, even in the non-dilated aorta [<xref ref-type="bibr" rid="B24-cells-05-00019">24</xref>]. MFS showed overexpression of TGF&#x3B2;resulting from a mutation of the <italic>FIBRILLIN-1</italic> gene [<xref ref-type="bibr" rid="B25-cells-05-00019">25</xref>]. On the other hand, in tissues obtained from patients with LDS, there is an apparent paradoxical increase in canonical TGF&#x3B2; signaling with an increased expression of SMAD2, CTGF and collagen. The opposing mechanisms underlying this unexpected and paradoxical effect are unclear. However, the situation is the same in LDS as that in BAV-associated aortopathy. Losartan, an AT<sub>1</sub>R antagonist, was suggested to reduce aortic dilation rates at least in a small pediatric cohort of MFS patients [<xref ref-type="bibr" rid="B26-cells-05-00019">26</xref>]. In the present study, the effect of losartan on the TGF&#x3B2; signaling pathway was investigated due to the similarity of aortic dilation to those in MFS and LDS.</p>
      <p>In addition to the genes <italic>TGF&#x3B2;1</italic>, <italic>TGF&#x3B2;R1</italic> and <italic>SMAD3,</italic> the gene encoding <italic>auxiliary receptor</italic> for TGF&#x3B2; endoglin was significantly downregulated after losartan treatment. Endoglin is involved in angiogenesis and vessel homoeostasis; an <italic>endoglin</italic> gene mutation leads to hereditary hemorrhagic telangiectasia [<xref ref-type="bibr" rid="B27-cells-05-00019">27</xref>]. Endoglin regulates the expression and activation of endothelial nitric oxide synthase, which is believed to play a role in angiogenesis and in the composition of vascular resistance in aneurysm formation [<xref ref-type="bibr" rid="B28-cells-05-00019">28</xref>]. Endoglin plays a pivotal role in the differentiation of neural crest cells into the VSMC that populate the aorta. Mancini <italic>et al.</italic> demonstrated that in <italic>endoglin <sup>&#x2212;</sup>/<sup>&#x2212;</sup></italic> mice, defective VSMC development occurs, which leads to the assumption that endoglin plays an important role in vessel wall composition on aneurysm formation [<xref ref-type="bibr" rid="B29-cells-05-00019">29</xref>]. On the other hand, it has been shown that TGF&#x3B2; and endoglin expressions are both elevated in cultured VSMCs derived from MFS patients. Losartan, an AT<sub>1</sub>R blocker, prevents aneurysm progression in MFS by decreasing TGF&#x3B2; activity [<xref ref-type="bibr" rid="B30-cells-05-00019">30</xref>,<xref ref-type="bibr" rid="B31-cells-05-00019">31</xref>]. In our study, the expression of TGF&#x3B2; and endoglin was decreased after treating a VSMC culture with losartan. This indicates the beneficial effects of losartan on the overexpression of TGF&#x3B2; signaling pathway proteins. Whether the differences in TGF&#x3B2; and endoglin levels in BAV patients are some of the causes of aneurysm development in BAV is unclear. Further investigations are warranted to clarify the effect of these proteins. A previous study showed direct dysregulation caspase-3 signaling in VSMCs isolated from BAV patients [<xref ref-type="bibr" rid="B20-cells-05-00019">20</xref>]. We are planning to induce apoptosis in primary VSMCs and to investigate the caspase-3 activity and signaling pathway in those cells in comparison with immortalized WG-59 cells. As the next step, we are planning on silencing important pathways (fibroblast growth factor, caspase-3 and endoglin [<xref ref-type="bibr" rid="B32-cells-05-00019">32</xref>]) for specific studies to improve our understanding of the mechanisms associated with apoptosis signaling in BAV.</p>
    </sec>
    <sec id="sec5-cells-05-00019">
      <title>5. Study Limitation</title>
      <p>We are aware of the fact that we only present the generation of one cell line in this study and that multiple chromosomal abnormalities in our cell line may affect the results and limit the comparability of these cells with other primary cell culture. An update of the literature, however, scored no results regarding the generation of human VSMC culture isolated from BAV patients, enabling investigation of BAV ascending aorta.</p>
      <p>Losartan should be metabolized to gain an activated form available for the organism. Telmisartan would be more suitable for <italic>in vitro</italic> usage. The application of telmisartan as an activated form of angiotensin II blocker, which on its part activates eNOS, will be one of our future projects. Telmisartan is known to decrease inflammatory protein expression, such as C- reactive protein in coronary plaque components [<xref ref-type="bibr" rid="B33-cells-05-00019">33</xref>]. However, according to our experience and previous results, only low inflammatory processes are detected in ascending aorta of BAV [<xref ref-type="bibr" rid="B34-cells-05-00019">34</xref>,<xref ref-type="bibr" rid="B35-cells-05-00019">35</xref>].</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors would like to acknowledge and thank the Leducq Fondation for supporting our work and giving us the opportunity to study BAV aortopathy over the coming years. Furthermore, we would like to thank the team of Department of Cardiac and Thoracic Vascular Surgery, Luebeck, Germany, as well as Merck Research Laboratories (New Jersey, USA) for supplying us with losartan.</p>
    </ack>
    <notes>
      <title>Author Contributions</title>
      <p>S.A.M conceived and designed the experiments; S.A.M., G.B., T.F., A.R., P.L-K. and D.S-B. performed the experiments; S.A.M. and J.Y. analyzed the data; P.R. contributed with software tools; S.A.M. P.L-K. and D.S-B wrote the paper.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-cells-05-00019">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frid</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Dempsey</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Durmowicz</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Stenmark</surname>
              <given-names>K.R.</given-names>
            </name>
          </person-group>
          <article-title>Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease</article-title>
          <source>Arterioscler. Thromb. Vasc. Biol.</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>1203</fpage>
          <lpage>1209</lpage>
          <pub-id pub-id-type="doi">10.1161/01.ATV.17.7.1203</pub-id>
          <pub-id pub-id-type="pmid">9261247</pub-id>
        </citation>
      </ref>
      <ref id="B2-cells-05-00019">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaper</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>W.D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of coronary collateral vessel growth</article-title>
          <source>Circ.Res.</source>
          <year>1996</year>
          <volume>79</volume>
          <fpage>911</fpage>
          <lpage>919</lpage>
          <pub-id pub-id-type="doi">10.1161/01.RES.79.5.911</pub-id>
          <pub-id pub-id-type="pmid">8888683</pub-id>
        </citation>
      </ref>
      <ref id="B3-cells-05-00019">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Louis</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Zahradka</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Vascular smooth muscle cell motility: From migration to invasion</article-title>
          <source>Exp. Clin. Cardiol.</source>
          <year>2010</year>
          <volume>15</volume>
          <fpage>e75</fpage>
          <lpage>e85</lpage>
          <pub-id pub-id-type="pmid">21264073</pub-id>
        </citation>
      </ref>
      <ref id="B4-cells-05-00019">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Candales</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Wickline</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms</article-title>
          <source>Am. J. Pathol.</source>
          <year>1997</year>
          <volume>150</volume>
          <fpage>993</fpage>
          <lpage>1007</lpage>
          <pub-id pub-id-type="pmid">9060837</pub-id>
        </citation>
      </ref>
      <ref id="B5-cells-05-00019">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milewicz</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Kwartler</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Papke</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Regalado</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>J.</given-names>
            </name>
			<name>
              <surname>Reid</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: Evidence for a hyperplastic vasculomyopathy</article-title>
          <source>Genet. Med.</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>196</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1097/GIM.0b013e3181cdd687</pub-id>
          <pub-id pub-id-type="pmid">20130469</pub-id>
        </citation>
      </ref>
      <ref id="B6-cells-05-00019">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guo</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Papke</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Tran-Fadulu</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Regalado</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Avidan</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Pannu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Willing</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Sparks</surname>
              <given-names>E.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>617</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2009.04.007</pub-id>
          <pub-id pub-id-type="pmid">19409525</pub-id>
        </citation>
      </ref>
      <ref id="B7-cells-05-00019">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grewal</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gittenberger-de Groot</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Poelmann</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Klautz</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Lindeman</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Goumans</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Palmen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Bogers</surname>
              <given-names>A.J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ascending aorta dilation in association with bicuspid aortic valve: A maturation defect of the aortic wall</article-title>
          <source>J. Thorac. Cardiovasc. Surg.</source>
          <year>2014</year>
          <volume>148</volume>
          <fpage>1583</fpage>
          <lpage>1590</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2014.01.027</pub-id>
          <pub-id pub-id-type="pmid">24560417</pub-id>
        </citation>
      </ref>
      <ref id="B8-cells-05-00019">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Della Corte</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Body</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Booher</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Schaefers</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Milewski</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Michelena</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>Evangelista</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pibarot</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Limongelli</surname>
              <given-names>G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surgical treatment of bicuspid aortic valve disease: Knowledge gaps and research perspectives</article-title>
          <source>J. Thorac Cardiovasc Surg.</source>
          <year>2014</year>
          <volume>147</volume>
          <fpage>1749</fpage>
          <lpage>1757</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2014.01.021</pub-id>
          <pub-id pub-id-type="pmid">24534676</pub-id>
        </citation>
      </ref>
      <ref id="B9-cells-05-00019">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fedak</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Borger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Butany</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Weisel</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>Bicuspid aortic valve disease: Recent insights in pathophysiology and treatment</article-title>
          <source>Expert. Rev. Cardiovasc Ther.</source>
          <year>2005</year>
          <volume>3</volume>
          <fpage>295</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1586/14779072.3.2.295</pub-id>
          <pub-id pub-id-type="pmid">15853603</pub-id>
        </citation>
      </ref>
      <ref id="B10-cells-05-00019">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirby</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Waldo</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Role of neural crest in congenital heart disease</article-title>
          <source>Circulation</source>
          <year>1990</year>
          <volume>82</volume>
          <fpage>332</fpage>
          <lpage>340</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.82.2.332</pub-id>
          <pub-id pub-id-type="pmid">2197017</pub-id>
        </citation>
      </ref>
      <ref id="B11-cells-05-00019">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindsay</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>H.C.</given-names>
            </name>
          </person-group>
          <article-title>Lessons on the pathogenesis of aneurysm from heritable conditions</article-title>
          <source>Nature</source>
          <year>2011</year>
          <volume>473</volume>
          <fpage>308</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1038/nature10145</pub-id>
          <pub-id pub-id-type="pmid">21593863</pub-id>
        </citation>
      </ref>
      <ref id="B12-cells-05-00019">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habashi</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Judge</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Loeys</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Calvi</surname>
              <given-names>C.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>312</volume>
          <fpage>117</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1124287</pub-id>
          <pub-id pub-id-type="pmid">16601194</pub-id>
        </citation>
      </ref>
      <ref id="B13-cells-05-00019">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kazmierczak</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bartnitzke</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hartl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bullerdiek</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title><italic>In vitro</italic> transformation by the SV40 'early region' of cells from a human benign salivary gland tumor with a 12q13&#x2192;q15 rearrangement</article-title>
          <source>Cytogenet. Cell Genet.</source>
          <year>1990</year>
          <volume>53</volume>
          <fpage>37</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1159/000132891</pub-id>
        </citation>
      </ref>
      <ref id="B14-cells-05-00019">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golledge</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Eagle</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Acute aortic dissection</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>372</volume>
          <fpage>55</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(08)60994-0</pub-id>
        </citation>
      </ref>
      <ref id="B15-cells-05-00019">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Estrera</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Safi</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Huynh</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>S.N.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kurian</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Buja</surname>
              <given-names>L.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections</article-title>
          <source>J. Thorac. Cardiovasc. Surg.</source>
          <year>2006</year>
          <volume>131</volume>
          <fpage>671</fpage>
          <lpage>678</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2005.09.018</pub-id>
          <pub-id pub-id-type="pmid">16515922</pub-id>
        </citation>
      </ref>
      <ref id="B16-cells-05-00019">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shein</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Enders</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Multiplication and cytopathogenicity of Simian vacuolating virus 40 in cultures of human tissues</article-title>
          <source>Proc. Soc. Exp. Biol. Med.</source>
          <year>1962</year>
          <volume>109</volume>
          <fpage>495</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.3181/00379727-109-27246</pub-id>
          <pub-id pub-id-type="pmid">13911591</pub-id>
        </citation>
      </ref>
      <ref id="B17-cells-05-00019">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Girardi</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>F.C.</given-names>
            </name>
			<name>
              <surname>Koprowski</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>SV40-Induced transformation of human diploid cells: Crisis and recovery</article-title>
          <source>J. Cell Physiol.</source>
          <year>1965</year>
          <volume>65</volume>
          <fpage>69</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.1030650110</pub-id>
          <pub-id pub-id-type="pmid">14288316</pub-id>
        </citation>
      </ref>
      <ref id="B18-cells-05-00019">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shay</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>W.E.</given-names>
            </name>
			<name>
              <surname>Werbin</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Defining the molecular mechanisms of human cell immortalization</article-title>
          <source>Biochim. Biophys. Acta</source>
          <year>1991</year>
          <volume>1072</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">1850299</pub-id>
        </citation>
      </ref>
      <ref id="B19-cells-05-00019">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beamish</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kottke-Marchant</surname>
              <given-names>K.</given-names>
            </name>
			<name>
              <surname>Marchant</surname>
              <given-names>R.E.</given-names>
            </name>
          </person-group>
          <article-title>Molecular regulation of contractile smooth muscle cell phenotype: Implications for vascular tissue engineering</article-title>
          <source>Tissue Eng Part B Rev.</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>467</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1089/ten.teb.2009.0630</pub-id>
          <pub-id pub-id-type="pmid">20334504</pub-id>
        </citation>
      </ref>
      <ref id="B20-cells-05-00019">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Misfeld</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hanke</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Charitos</surname>
              <given-names>E.I.</given-names>
            </name>
            <name>
              <surname>Bullerdiek</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Belge</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kuehnel</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>H.H.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of caspase-3 differentially affects vascular smooth muscle cell apoptosis in the concave <italic>versus</italic> convex aortic sites in ascending aneurysms with a bicuspid aortic valve</article-title>
          <source>Ann. Anat.</source>
          <year>2010</year>
          <volume>192</volume>
          <fpage>145</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1016/j.aanat.2010.02.006</pub-id>
          <pub-id pub-id-type="pmid">20427168</pub-id>
        </citation>
      </ref>
      <ref id="B21-cells-05-00019">
        <label>21.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>H.H.</given-names>
            </name>
          </person-group>
          <source>Ascending Aneurysms in Bicuspid Aortic Valve</source>
          <publisher-name>INTECH Open Access Publisher</publisher-name>
          <publisher-loc>Rijeka, Croatia</publisher-loc>
          <year>2011</year>
          <fpage>161</fpage>
          <lpage>174</lpage>
        </citation>
      </ref>
      <ref id="B22-cells-05-00019">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonderman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gharehbaghi-Schnell</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wollenek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>I.M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms underlying aortic dilatation in congenital aortic valve malformation</article-title>
          <source>Circulation</source>
          <year>1999</year>
          <volume>99</volume>
          <fpage>2138</fpage>
          <lpage>2143</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.99.16.2138</pub-id>
          <pub-id pub-id-type="pmid">10217654</pub-id>
        </citation>
      </ref>
      <ref id="B23-cells-05-00019">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmid</surname>
              <given-names>F.X.</given-names>
            </name>
            <name>
              <surname>Bielenberg</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Haussler</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Keyser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Birnbaum</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve: Involvement and clinical relevance of smooth muscle cell apoptosis and expression of cell death-initiating proteins</article-title>
          <source>Eur. J. Cardiothorac. Surg.</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>537</fpage>
          <lpage>543</lpage>
          <pub-id pub-id-type="doi">10.1016/S1010-7940(02)00833-3</pub-id>
        </citation>
      </ref>
      <ref id="B24-cells-05-00019">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nataatmadja</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Summers</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm</article-title>
          <source>Circulation</source>
          <year>2003</year>
          <volume>108</volume>
          <supplement>(Suppl. S1)</supplement>
          <fpage>II329</fpage>
          <lpage>II334</lpage>
          <pub-id pub-id-type="doi">10.1161/01.cir.0000087660.82721.15</pub-id>
          <pub-id pub-id-type="pmid">12970255</pub-id>
        </citation>
      </ref>
      <ref id="B25-cells-05-00019">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dietz</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Loeys</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Carta</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Recent progress towards a molecular understanding of Marfan syndrome</article-title>
          <source>Am. J. Med. Genet. C Semin. Med. Genet.</source>
          <year>2005</year>
          <volume>139</volume>
          <fpage>4</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.c.30068</pub-id>
          <pub-id pub-id-type="pmid">16273535</pub-id>
        </citation>
      </ref>
      <ref id="B26-cells-05-00019">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brooke</surname>
              <given-names>B.S.</given-names>
            </name>
            <name>
              <surname>Habashi</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Judge</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Loeys</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>H.C.</given-names>
              <suffix>III</suffix>
            </name>
          </person-group>
          <article-title>Angiotensin II blockade and aortic-root dilation in Marfan's syndrome</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2008</year>
          <volume>358</volume>
          <fpage>2787</fpage>
          <lpage>2795</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0706585</pub-id>
          <pub-id pub-id-type="pmid">18579813</pub-id>
        </citation>
      </ref>
      <ref id="B27-cells-05-00019">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McAllister</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Grogg</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Gallione</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Baldwin</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Helmbold</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Markel</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>McKinnon</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Murrell</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1</article-title>
          <source>Nat.Genet.</source>
          <year>1994</year>
          <volume>8</volume>
          <fpage>345</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1294-345</pub-id>
          <pub-id pub-id-type="pmid">7894484</pub-id>
        </citation>
      </ref>
      <ref id="B28-cells-05-00019">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Radtke</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Saraei</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bullerdiek</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sorani</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nimzyk</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Karluss</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Belge</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Locally different endothelial nitric oxide synthase protein levels in ascending aortic aneurysms of bicuspid and tricuspid aortic valve</article-title>
          <source>Cardiol. Res. Pract.</source>
          <year>2012</year>
          <volume>2012</volume>
          <pub-id pub-id-type="doi">10.1155/2012/165957</pub-id>
          <pub-id pub-id-type="pmid">22745920</pub-id>
        </citation>
      </ref>
      <ref id="B29-cells-05-00019">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mancini</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Verdi</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Conley</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Nicola</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Spicer</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Oxburgh</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Vary</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Endoglin is required for myogenic differentiation potential of neural crest stem cells</article-title>
          <source>Dev. Biol.</source>
          <year>2007</year>
          <volume>308</volume>
          <fpage>520</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ydbio.2007.06.009</pub-id>
          <pub-id pub-id-type="pmid">17628518</pub-id>
        </citation>
      </ref>
      <ref id="B30-cells-05-00019">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaschina</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schrader</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Sommerfeld</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kemnitz</surname>
              <given-names>U.R.</given-names>
            </name>
            <name>
              <surname>Grzesiak</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Krikov</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation</article-title>
          <source>J. Hypertens.</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>2361</fpage>
          <lpage>2373</lpage>
          <pub-id pub-id-type="doi">10.1097/HJH.0b013e328313e547</pub-id>
          <pub-id pub-id-type="pmid">19008714</pub-id>
        </citation>
      </ref>
      <ref id="B31-cells-05-00019">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nataatmadja</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Prabowo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II Receptor Antagonism Reduces Transforming Growth Factor Beta and Smad Signaling in Thoracic Aortic Aneurysm</article-title>
          <source>Ochsner. J.</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>42</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">23532685</pub-id>
        </citation>
      </ref>
      <ref id="B32-cells-05-00019">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>H.H.</given-names>
            </name>
          </person-group>
          <article-title>Studies on Aortic and Aortic Valve Diseases</article-title>
          <source>Clin. Exp. Cardiol.</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>2</fpage>
          <lpage>5</lpage>
        </citation>
      </ref>
      <ref id="B33-cells-05-00019">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamaguchi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wakatsuki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Soeki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Niki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Taketani</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Oeduka</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kusunose</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ise</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Iwase</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients</article-title>
          <source>Circ. J.</source>
          <year>2014</year>
          <volume>78</volume>
          <fpage>240</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1253/circj.CJ-13-0741</pub-id>
          <pub-id pub-id-type="pmid">24189463</pub-id>
        </citation>
      </ref>
      <ref id="B34-cells-05-00019">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grewal</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Franken</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Goumans</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Lindeman</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Jongbloed</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Deruiter</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Klautz</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Bogers</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Poelmann</surname>
              <given-names>R.E.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: Relevance for therapy?</article-title>
          <source>Heart Vessels.</source>
          <year>2015</year>
          <pub-id pub-id-type="doi">10.1007/s00380-015-0703-z</pub-id>
          <pub-id pub-id-type="pmid">26129868</pub-id>
        </citation>
      </ref>
      <ref id="B35-cells-05-00019">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lehsau</surname>
              <given-names>A.-C.</given-names>
            </name>
            <name>
              <surname>Lazar-Karsten</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Schult-Badusche</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Loeys</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Mohamed</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>Genetic Basis, Pathogenesis and Histopathology of Aortopathy in Bicuspid Aortic Valve and Marfan Syndrome</article-title>
          <year>2015</year>
          <volume>3</volume>
          <fpage>55</fpage>
          <lpage>82</lpage>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figures and Tables</title>
      <fig id="cells-05-00019-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>(<bold>A</bold>) Initial foci of transformed cells 26 days post-transfection in the bright field microscope. Foci are clearly distinguishable among the cultured and transfected cells. (<bold>B</bold>) GFP-labeled T-antigen expression in transfected cells. (<bold>C</bold>) Immortalized confluent WG-59 in comparison with non-transfected, primary confluent VSMCs; 10-fold enlargement (<bold>D</bold>). (<bold>E</bold>) WG-59 cell culture, third day of 20. Passage; 10-fold enlargement. (<bold>F</bold>) WG-59 cell culture, sixth day of 20. Passage; 10-fold enlargement.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g001.tif"/>
      </fig>
      <fig id="cells-05-00019-f002" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Illustration of detected chromosomes in WG-59 immortalized cultured cells in display colors, showing a pseudotriploid cell line with several aberrations.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g002.tif"/>
      </fig>
      <fig id="cells-05-00019-f003" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Electropherogram of the short tandem repeat (STR) profiling of (<bold>A</bold>) the WG-59 cell line and (<bold>B</bold>) the WG-59 donor tissue.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g003.tif"/>
      </fig>
      <fig id="cells-05-00019-f004" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Purity analysis of isolated VSMCs with flow cytometry showing &#x3B1;-actin and myosin heavy chain-positive cells at the 20th passage and 80%&#x2013;90% confluency. (<bold>A</bold>) Isotype control; (<bold>B</bold>) WG-59 cells; (<bold>C</bold>&#x2013;<bold>D</bold>) purity analysis of isolated VSMCs with flow cytometry showing &#x3B1;-actin- and calponin-positive cells at the 20th passage and 80%&#x2013;90% confluency; (<bold>E</bold>&#x2013;<bold>F</bold>) purity analysis of isolated VSMCs with flow cytometry showing myosin heavy chain- and calponin-positive cells at the 20th passage and 80%&#x2013;90% confluency; (<bold>G</bold>&#x2013;<bold>H</bold>) purity analysis of isolated VSMCs with flow cytometry showing smoothelin and the isotype control of WG-59 cells at the 20th passage and 80%&#x2013;90% confluency. Histogram plot of Smoothelin expression (G). Isotype control in pseudo color plot (H).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g004.tif"/>
      </fig>
      <fig id="cells-05-00019-f005" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Correlation between the signal intensities of TGF&#x3B2;-pathway genes. Expression analysis in losartan-treated and untreated cells. Cells treated with losartan are plotted against untreated cells. The scatter plot shows a positive tendency with a strong correlation between the two samples.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g005.tif"/>
      </fig>
      <fig id="cells-05-00019-f006" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Single real-time RT-PCR of endoglin after WG-59 treatment with increasing losartan concentrations. Increasing the losartan concentration could not downregulate endoglin expression significantly.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cells-05-00019-g006.tif"/>
      </fig>
      <table-wrap id="cells-05-00019-t001" position="float">
        <object-id pub-id-type="pii">cells-05-00019-t001_Table 1</object-id>
        <label>Table 1</label>
        <caption>
          <p>Karyotype of the examined immortalized cell culture showing several aberrations in different chromosomes. SKY, spectral karyotyping.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Composite Karyotype SKY:</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" style="border-bottom:solid thin">70-91,XX,-Y[11],-Y[12],der(2)t(2;6)x2[11],-3[3],-4[4],der(6)t(6;15)[2],der(6)t(6;15der(8)t(9;8;2)x2[12],der(8)t(8;18)[7],der(8)t(8;18)x2[5],-9[4],+9[2],der(9)t(5;9)[5],der(9)t(5;9)x2[6],-10[4],-11[3],der(11)t(8;11)x2[7],der(12)t(5;12)x2[4],-13[7],-13[3],rob(13;14)[4],rob(13;14)x2[7],-14[5],-14[7],der(14)t(14,19)[4],der(14)t(14,19)x2[4],-15[12],-15[12], der(15)t(15;16)x2[9],-16[5], del(16)x2[8],der(16)t(16;20)x2[3],-17[4],-18[11],-18[7],der(18)t(5;18)[2],der(18)t(11;18)x2[7],-19[2]-19[10],-20[3],-20[2],der(20)t(20;22)x2[9],-21[3],-22[12],-22[12][cp12]</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="cells-05-00019-t002" position="float">
        <object-id pub-id-type="pii">cells-05-00019-t002_Table 2</object-id>
        <label>Table 2</label>
        <caption>
          <p>Allelic list of the WG-59 cell line and tissue donor STR loci profiling using 8 different polymorph loci, performed by DSMZ, Germany, showing that these two samples are of the same origin.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Marker</th>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WG-59 Cells</th>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">WG-59 Tissue</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">D5</td>
              <td align="center" valign="middle">10</td>
              <td align="center" valign="middle">10</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D5&#x2019;</td>
              <td align="center" valign="middle">12</td>
              <td align="center" valign="middle">12</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D13</td>
              <td align="center" valign="middle">11</td>
              <td align="center" valign="middle">11</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D13&#x2019;</td>
              <td align="center" valign="middle">11</td>
              <td align="center" valign="middle">11</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D7</td>
              <td align="center" valign="middle">9</td>
              <td align="center" valign="middle">9</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D7&#x2019;</td>
              <td align="center" valign="middle">10</td>
              <td align="center" valign="middle">10</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D16</td>
              <td align="center" valign="middle">12</td>
              <td align="center" valign="middle">12</td>
            </tr>
            <tr>
              <td align="center" valign="middle">D16&#x2019;</td>
              <td align="center" valign="middle">13</td>
              <td align="center" valign="middle">13</td>
            </tr>
            <tr>
              <td align="center" valign="middle">vWA</td>
              <td align="center" valign="middle">14</td>
              <td align="center" valign="middle">14</td>
            </tr>
            <tr>
              <td align="center" valign="middle">vWA&#x2019;</td>
              <td align="center" valign="middle">15</td>
              <td align="center" valign="middle">15</td>
            </tr>
            <tr>
              <td align="center" valign="middle">TH01</td>
              <td align="center" valign="middle">9</td>
              <td align="center" valign="middle">9</td>
            </tr>
            <tr>
              <td align="center" valign="middle">TH01&#x2019;</td>
              <td align="center" valign="middle">9.3</td>
              <td align="center" valign="middle">9.3</td>
            </tr>
            <tr>
              <td align="center" valign="middle">TPOX</td>
              <td align="center" valign="middle">8</td>
              <td align="center" valign="middle">8</td>
            </tr>
            <tr>
              <td align="center" valign="middle">TPOX&#x2019;</td>
              <td align="center" valign="middle">11</td>
              <td align="center" valign="middle">11</td>
            </tr>
            <tr>
              <td align="center" valign="middle">CFS1</td>
              <td align="center" valign="middle">11</td>
              <td align="center" valign="middle">11</td>
            </tr>
            <tr>
              <td align="center" valign="middle">CSF1&#x2019;</td>
              <td align="center" valign="middle">11</td>
              <td align="center" valign="middle">11</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Amel</td>
              <td align="center" valign="middle">X</td>
              <td align="center" valign="middle">X</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">Amel&#x2019;</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">X</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Y</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="cells-05-00019-t003" position="float">
        <object-id pub-id-type="pii">cells-05-00019-t003_Table 3</object-id>
        <label>Table 3</label>
        <caption>
          <p>Significantly regulated genes in WG-59 after losartan-treatment compared to untreated cells. &#x2212;, downregulation; +, upregulation.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Gene</th>
              <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Description</th>
              <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Gene Bank</th>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Fold Change</th>
              <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin"><italic>t</italic>-Test</th>
            </tr>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin">1 &#xB5;M Losartan <italic>vs</italic>. Control</th>
              <th align="center" valign="middle" style="border-bottom:solid thin"><italic>p</italic>-Value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>ACVR2</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Activin A receptor, type IIA</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_001616.3</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.16</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0274</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>BAMBI</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">BMP and activin membrane-bound inhibitor</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_012342.2</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.10</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0273</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>BMP4</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Bone morphogenetic protein 4</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_001202.3</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.12</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0325</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>BMPER</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">BMP binding endothelial regulator</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_133468</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.16</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0121</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>CDC25A</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Cell division cycle 25A</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_001789.2</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.24</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0008</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>CST3</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Cystatin C</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NC_000020.10</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.11</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0305</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>ENG</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Endoglin</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_000118</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.14</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0052</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>FST</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Follistatin</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_013409</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.13</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0099</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>GDF5</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Growth Differentiation Factor 5</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_000557</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.26</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0091</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>JUN</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Jun Proto-Oncogene</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_002228</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.06</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0479</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>PLAU</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Plasminogen Activator, urokinase</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_002658</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.07</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0052</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>SMAD3</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">SMAD family member 3</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_005902</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">1.01</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0335</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>SOX4</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">SRY (sex determining region Y)-box 4</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_003107</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.25</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0061</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>STAT1</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Signal transducer and activator of transcription, 1.91 kD</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_007315</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.08</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0015</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>TGFB1</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Transforming growth factor beta 1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_000660</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">1.02</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0460</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>TGFBI</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Transforming growth factor, beta-induced, 68 kDa</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_000358</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.12</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0316</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>TGFBR1</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Transforming growth factor beta, receptor 1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_004612</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.20</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0028</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin"><italic>HPRT1</italic></td>
              <td align="center" valign="middle" style="border-bottom:solid thin">Hypoxanthine phosphoribosyltransferase1</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">NM_000194</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">&#x2212;1.04</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">0.0396</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </back>
</article>
